[Clinical significance and problems of treatment of patients with heparin-induced thrombocytopenia].
Barkagan
Z S
ZS
D000328:Adult; D000925:Anticoagulants / Q000009:adverse effects*; D003029:Coagulants / Q000627:therapeutic use; D005260:Female; D006493:Heparin / Q000009:adverse effects*; D006495:Heparin, Low-Molecular-Weight / Q000009:adverse effects; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D010956:Plasmapheresis; D010978:Platelet Factor 4 / Q000627:therapeutic use; D011247:Pregnancy; D011250:Pregnancy Complications, Hematologic / Q000139:chemically induced* / Q000628:therapy*; D013921:Thrombocytopenia / Q000139:chemically induced* / Q000145:classification / Q000628:therapy*
D000925:Anticoagulants; D003029:Coagulants; D006495:Heparin, Low-Molecular-Weight; D010978:Platelet Factor 4; D006493:Heparin